Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.

abstract：INTRODUCTION:Angiogenesis inhibition represents a rational therapeutic strategy in the management of solid tumors. Brivanib is a dual tyrosine kinase inhibitor with selectivity against VEFGR-2 and FGFR. AREAS COVERED:This review provides an updated summary of preclinical and clinical experience with brivanib in cancer...

journal_title：Expert opinion on investigational drugs

authors： Diaz-Padilla I,Siu LL

更新日期：2011-04-01 00:00:00

abstract：:Recently there have been considerable advances made in the treatment of multiple sclerosis. For the first time since its initial clinical description in the 1800s, there are now available several medications which unequivocally exert favourable clinical effects through the lowering of the biological activity of the hu...

journal_title：Expert opinion on investigational drugs

authors： Goodin DS

更新日期：2000-04-01 00:00:00

abstract：:Suicide gene therapy is the approach whereby the genetic alteration of a cell renders it susceptible to an otherwise non-toxic prodrug. Suicide gene therapy for solid tumours has progressed rapidly since the concept was originally described: nearly all tumour types have been explored, with some, such as glioma, melano...

journal_title：Expert opinion on investigational drugs

authors： Perry MJ,Todryk SM,Dalgleish AG

更新日期：1999-06-01 00:00:00

abstract：INTRODUCTION:Basal-like breast cancer is characterized by being triple negative and aggressive. Defects in DNA repair is a promising therapeutic target as BRCA alterations are found in 11 to 42% of these tumors, with a frequency varying according to family history and ethnicity. The oral PARP inhibitors exploit this de...

journal_title：Expert opinion on investigational drugs

authors： Robert M,Frenel JS,Gourmelon C,Patsouris A,Augereau P,Campone M

更新日期：2017-06-01 00:00:00

abstract：INTRODUCTION:Despite the heterogeneity of prostate cancer (PCa), androgen stimulation is fundamental to its development, growth, and lethality. Therefore, the blockade of androgen receptor (AR) signaling is critical to controlling the disease, even after progression with castrate levels of androgens. AREAS COVERED:We ...

journal_title：Expert opinion on investigational drugs

authors： Isaacsson Velho P,Carducci MA

更新日期：2018-10-01 00:00:00

abstract：:Introduction: Plasma kallikrein is a  mediator of vascular leakage and inflammation. Activation of plasma kallikrein can induce features of diabetic macular edema (DME) in preclinical models. Human vitreous shows elevated plasma kallikrein levels in patients with DME. Because of the incomplete response of some patient...

journal_title：Expert opinion on investigational drugs

authors： Bhatwadekar AD,Kansara VS,Ciulla TA

更新日期：2020-03-01 00:00:00

abstract：:Binding of microbial cell surface adhesins to host receptor molecules is a critical early step in microbial infection and pathogenesis. Anti-adhesive strategies aimed at blocking this interaction offer an attractive means of preventing infection at an early stage. The strategy should reduce the likelihood of resistant...

journal_title：Expert opinion on investigational drugs

authors： Kelly CG,Younson JS

更新日期：2000-08-01 00:00:00

abstract：:All of the glucose-lowering agents available today for the treatment of diabetes resulted from the in vivo antidiabetic drug discovery approach. This is not surprising given the limited understanding of the biochemical basis of diabetes. With new developments in the elucidation of the biochemistry and physiology of di...

journal_title：Expert opinion on investigational drugs

authors： Luo J

更新日期：1998-06-01 00:00:00

abstract：:Early breast carcinoma is defined as pathological stage 1 (pT1N0M0) tumour and its incidence has recently increased possibly due to the advent of mammography based mass screening. Overall survival of these patients is in general excellent, but more than 20% of them will eventually develop distant metastasis and die. T...

journal_title：Expert opinion on investigational drugs

authors： Sasano H

更新日期：2010-04-01 00:00:00

abstract：:The discovery of new antibacterial drugs can be based either upon empirical screening methods or structure-based design. Empirical methods utilise both intact bacteria and isolated biochemical targets for high throughput screening of natural product or chemical libraries to detect inhibitor leads. Structure-based meth...

journal_title：Expert opinion on investigational drugs

authors： Chopra I

更新日期：1997-08-01 00:00:00

abstract：INTRODUCTION:Chagas disease treatment relies on the lengthy administration of benznidazole and/or nifurtimox, which have frequent toxicity associated. The disease, caused by the parasite Trypanosoma cruzi, is mostly diagnosed at its chronic phase when life-threatening symptomatology manifest in approximately 30% of tho...

journal_title：Expert opinion on investigational drugs

authors： Martínez-Peinado N,Cortes-Serra N,Losada-Galvan I,Alonso-Vega C,Urbina JA,Rodríguez A,VandeBerg JL,Pinazo MJ,Gascon J,Alonso-Padilla J

更新日期：2020-09-01 00:00:00

abstract：:A disintegrin and metalloproteases (ADAMs) are zinc-dependent trans-membrane metalloproteases that shed the extracellular domains of membrane-bound growth factors, cytokines and receptors. Key functions of ADAMs have emerged in ErbB signalling pathways as being sheddases for multiple ErbB ligands. As the ErbB pathway ...

journal_title：Expert opinion on investigational drugs

authors： Zhou BB,Fridman JS,Liu X,Friedman SM,Newton RC,Scherle PA

更新日期：2005-06-01 00:00:00

abstract：:The management of acute myocardial infarction (AMI) has changed dramatically over the last two decades, with the addition of fibrinolytic agents and primary coronary intervention (PCI). The more recent development of the glycoprotein (GP) IIb/IIIa antagonists, a new class of potent antiplatelet drugs, has the potentia...

journal_title：Expert opinion on investigational drugs

authors： Ferguson JJ,Vaisman D

更新日期：2001-11-01 00:00:00

abstract：:Disruption of a vulnerable atherosclerotic plaque is well-recognised as the primary cause of stroke, non-fatal myocardial infarction and sudden cardiac death. Novel therapeutic agents are being developed to stabilise such plaques. The initial evaluation of these drugs would be facilitated by the use of non-invasive im...

journal_title：Expert opinion on investigational drugs

authors： Sosnovik DE,Muller JE,Kathiresan S,Brady TJ

更新日期：2002-05-01 00:00:00

abstract：INTRODUCTION:Since the discovery of the activating V617F mutation in Janus kinase 2 (JAK2), a number of pharmacologic inhibitors of JAK2 have entered clinical trials for patients with myelofibrosis. However, ruxolitinib, approved in 2011, remains the only one currently available for treatment of myelofibrosis, with man...

journal_title：Expert opinion on investigational drugs

authors： Bose P,Abou Zahr A,Verstovsek S

更新日期：2017-06-01 00:00:00

abstract：INTRODUCTION:Influenza viral ribonucleoprotein complexes (vRNPs) play a key role in viral transcription and replication; hence, the recent development of novel anti-influenza drugs targeting vRNPs has garnered widespread interest. AREAS COVERED:We discuss the function of the constituents of vRNPs and summarize those v...

journal_title：Expert opinion on investigational drugs

authors： Yang J,Huang Y,Liu S

更新日期：2019-05-01 00:00:00

abstract：INTRODUCTION:Vascular-disrupting agents (VDAs) are a new class of oncology drugs, which specifically target established tumor neovasculature and have a relatively low toxicity profile. VDAs generally have non-overlapping side effects when concomitantly used with conventional cytotoxics. Several members of the VDA class...

journal_title：Expert opinion on investigational drugs

authors： Mita MM,Sargsyan L,Mita AC,Spear M

更新日期：2013-03-01 00:00:00

abstract：:Introduction: A compound that simultaneously inhibits PDE3 and PDE4 should increase airway caliber by relaxing the smooth muscle and, simultaneously, suppress airway inflammatory responses. Ensifentrine (RPL554) is considered a PDE3/4 inhibitor, although its affinity for PDE3 is 3,440 times higher than that for PDE4, ...

journal_title：Expert opinion on investigational drugs

authors： Cazzola M,Calzetta L,Rogliani P,Matera MG

更新日期：2019-10-01 00:00:00

abstract：BACKGROUND:Chronic hepatitis C virus (HCV) infection is a worldwide health problem. Response rates to current standard of treatment (pegylated IFNs and ribavirin) are low in patients with the prevailing genotype 1. OBJECTIVE:To review papers published or presented at recent international meetings showing the results o...

journal_title：Expert opinion on investigational drugs

authors： Vento S,Cainelli F,Temesgen Z

更新日期：2008-11-01 00:00:00

abstract：:The annual meeting of the American Diabetes Association was held in Boston, MA. There were over 6500 participants, one-third from overseas, and 1103 papers were presented. Abstracts from the meeting have been published, from which abstract numbers are given below, e.g., (A141). Considerable progress has been made in u...

journal_title：Expert opinion on investigational drugs

authors： Colca J

更新日期：1997-08-01 00:00:00

abstract：INTRODUCTION:Circadian rhythm is a natural endogenous process occurring roughly every 24 hours. Circadian rhythm dysfunction is involved in diabetic retinopathy (DR) pathogenesis. Interestingly, there are investigational drugs that exhibit potential in the treatment of DR by targeting circadian rhythm dysfunction. ARE...

journal_title：Expert opinion on investigational drugs

authors： Bhatwadekar AD,Rameswara V

更新日期：2020-12-01 00:00:00

abstract：:Introduction: The armamentarium of antileishmanial drugs is small. It is further being threatened by the development of resistance and decreasing sensitivity to the available drugs. The development of newer drugs is sorely needed. Areas covered: The authors have based their review on a literature search performed usin...

journal_title：Expert opinion on investigational drugs

authors： Sundar S,Chakravarty J

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a dismal prognosis. With the emergence of monoclonal antibodies and tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR), several drugs were developed and tested in HNSCC. To date, the monoclonal...

journal_title：Expert opinion on investigational drugs

authors： Elicin O,Ozsahin M

更新日期：2016-06-01 00:00:00

abstract：INTRODUCTION:Type 2 diabetes is a chronic metabolic disease characterized by persistent hyperglycemia resulting from progressive deficient of insulin in patients with a background of insulin resistance. Current treatment algorithms recommended by American Diabetes Association/The European Association for the Study of D...

journal_title：Expert opinion on investigational drugs

authors： Tan X,Cao X,Zhou M,Zou P,Hu J

更新日期：2017-09-01 00:00:00

abstract：INTRODUCTION:Epithelial ovarian cancer (EOC) is the fourth commonest cause of female cancer death in the developed world. Although progress in treatment has improved survival, ∼ 80% of patients with advanced EOC will experience a recurrence and eventually will become resistant to chemotherapy. The aim of treatment for ...

journal_title：Expert opinion on investigational drugs

authors： Marchetti C,Ledermann JA,Benedetti Panici P

更新日期：2015-01-01 00:00:00

abstract：:This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in...

journal_title：Expert opinion on investigational drugs

authors： Kelland LR

更新日期：2000-12-01 00:00:00

abstract：INTRODUCTION:Approximately 300 million people worldwide are currently affected by asthma. Improvements in the understanding of the mechanisms involved in such inflammatory airway disorders has led to the recognition of new therapeutic approaches. Heparin, a widely used anticoagulant, has been shown to be beneficial in ...

journal_title：Expert opinion on investigational drugs

authors： Shastri MD,Peterson GM,Stewart N,Sohal SS,Patel RP

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:Age-related macular degeneration (AMD) affects > 14 million individuals worldwide. Although 90% of patients with AMD have the dry form, neovascular AMD accounts for the vast majority of patients who develop legal blindness. Until recently, few treatment options existed for treatment of neovascular AMD. The a...

journal_title：Expert opinion on investigational drugs

authors： Dixon JA,Oliver SC,Olson JL,Mandava N

更新日期：2009-10-01 00:00:00

abstract：INTRODUCTION:Medical treatment of brain metastases (BM) is still a controversial issue in cancer therapy being mainly limited by the existence of the BBB. Temozolomide (TMZ) can cross BBB and several clinical trials have been performed attempting to demonstrate the activity of TMZ in combination with whole brain radiot...

journal_title：Expert opinion on investigational drugs

authors： Addeo R,Caraglia M

更新日期：2011-07-01 00:00:00

abstract：INTRODUCTION:The small tyrosine kinase inhibitor Imatinib Mesylate (Gleevec) protects against diabetes, but it is not known how. AREAS COVERED:It has been suggested that islet amyloid and fibrotic deposits promote beta-cell failure and death, leading to Type-2 diabetes. As Imatinib is known to possess anti-fibrotic/am...

journal_title：Expert opinion on investigational drugs

authors： Welsh N

更新日期：2012-11-01 00:00:00